These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 29785777)

  • 1. Paradoxical effect of baclofen on social behavior in the fragile X syndrome mouse model.
    Zeidler S; Pop AS; Jaafar IA; de Boer H; Buijsen RAM; de Esch CEF; Nieuwenhuizen-Bakker I; Hukema RK; Willemsen R
    Brain Behav; 2018 Jun; 8(6):e00991. PubMed ID: 29785777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. R-Baclofen Reverses a Social Behavior Deficit and Elevated Protein Synthesis in a Mouse Model of Fragile X Syndrome.
    Qin M; Huang T; Kader M; Krych L; Xia Z; Burlin T; Zeidler Z; Zhao T; Smith CB
    Int J Neuropsychopharmacol; 2015 Mar; 18(9):. PubMed ID: 25820841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen.
    Henderson C; Wijetunge L; Kinoshita MN; Shumway M; Hammond RS; Postma FR; Brynczka C; Rush R; Thomas A; Paylor R; Warren ST; Vanderklish PW; Kind PC; Carpenter RL; Bear MF; Healy AM
    Sci Transl Med; 2012 Sep; 4(152):152ra128. PubMed ID: 22993295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GABA-B Agonist Baclofen Normalizes Auditory-Evoked Neural Oscillations and Behavioral Deficits in the
    Sinclair D; Featherstone R; Naschek M; Nam J; Du A; Wright S; Pance K; Melnychenko O; Weger R; Akuzawa S; Matsumoto M; Siegel SJ
    eNeuro; 2017; 4(1):. PubMed ID: 28451631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deficits in the activity of presynaptic γ-aminobutyric acid type B receptors contribute to altered neuronal excitability in fragile X syndrome.
    Kang JY; Chadchankar J; Vien TN; Mighdoll MI; Hyde TM; Mather RJ; Deeb TZ; Pangalos MN; Brandon NJ; Dunlop J; Moss SJ
    J Biol Chem; 2017 Apr; 292(16):6621-6632. PubMed ID: 28213518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deletion of Fmr1 in parvalbumin-expressing neurons results in dysregulated translation and selective behavioral deficits associated with fragile X syndrome.
    Kalinowska M; van der Lei MB; Kitiashvili M; Mamcarz M; Oliveira MM; Longo F; Klann E
    Mol Autism; 2022 Jun; 13(1):29. PubMed ID: 35768828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperexcitability in the Olfactory Bulb and Impaired Fine Odor Discrimination in the
    Kuruppath P; Xue L; Pouille F; Jones ST; Schoppa NE
    J Neurosci; 2023 Nov; 43(48):8243-8258. PubMed ID: 37788940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fragile X mental retardation protein replacement restores hippocampal synaptic function in a mouse model of fragile X syndrome.
    Zeier Z; Kumar A; Bodhinathan K; Feller JA; Foster TC; Bloom DC
    Gene Ther; 2009 Sep; 16(9):1122-9. PubMed ID: 19571888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective Deletion of Astroglial FMRP Dysregulates Glutamate Transporter GLT1 and Contributes to Fragile X Syndrome Phenotypes In Vivo.
    Higashimori H; Schin CS; Chiang MS; Morel L; Shoneye TA; Nelson DL; Yang Y
    J Neurosci; 2016 Jul; 36(27):7079-94. PubMed ID: 27383586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baclofen-associated neurophysiologic target engagement across species in fragile X syndrome.
    Jonak CR; Pedapati EV; Schmitt LM; Assad SA; Sandhu MS; DeStefano L; Ethridge L; Razak KA; Sweeney JA; Binder DK; Erickson CA
    J Neurodev Disord; 2022 Sep; 14(1):52. PubMed ID: 36167501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of Phosphodiesterase 2A Activity in the Pathophysiology of Fragile X Syndrome.
    Maurin T; Melancia F; Jarjat M; Castro L; Costa L; Delhaye S; Khayachi A; Castagnola S; Mota E; Di Giorgio A; Servadio M; Drozd M; Poupon G; Schiavi S; Sardone L; Azoulay S; Ciranna L; Martin S; Vincent P; Trezza V; Bardoni B
    Cereb Cortex; 2019 Jul; 29(8):3241-3252. PubMed ID: 30137253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations in CA1 hippocampal synapses in a mouse model of fragile X syndrome.
    Jawaid S; Kidd GJ; Wang J; Swetlik C; Dutta R; Trapp BD
    Glia; 2018 Apr; 66(4):789-800. PubMed ID: 29274095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered anxiety-related and social behaviors in the Fmr1 knockout mouse model of fragile X syndrome.
    Spencer CM; Alekseyenko O; Serysheva E; Yuva-Paylor LA; Paylor R
    Genes Brain Behav; 2005 Oct; 4(7):420-30. PubMed ID: 16176388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fragile X-like behaviors and abnormal cortical dendritic spines in cytoplasmic FMR1-interacting protein 2-mutant mice.
    Han K; Chen H; Gennarino VA; Richman R; Lu HC; Zoghbi HY
    Hum Mol Genet; 2015 Apr; 24(7):1813-23. PubMed ID: 25432536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synaptic vesicle dynamic changes in a model of fragile X.
    Broek JAC; Lin Z; de Gruiter HM; van 't Spijker H; Haasdijk ED; Cox D; Ozcan S; van Cappellen GWA; Houtsmuller AB; Willemsen R; de Zeeuw CI; Bahn S
    Mol Autism; 2016; 7():17. PubMed ID: 26933487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tau reduction attenuates autism-like features in Fmr1 knockout mice.
    Zhao S; Jiang X; Han L; Jiang Y; Wang Y; Meng J; Zhu X; Zhang X; Luo H; Zhang YW
    Mol Autism; 2023 Nov; 14(1):42. PubMed ID: 37936174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. STEP inhibition reverses behavioral, electrophysiologic, and synaptic abnormalities in Fmr1 KO mice.
    Chatterjee M; Kurup PK; Lundbye CJ; Hugger Toft AK; Kwon J; Benedict J; Kamceva M; Banke TG; Lombroso PJ
    Neuropharmacology; 2018 Jan; 128():43-53. PubMed ID: 28943283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic deletion of regulator of G-protein signaling 4 (RGS4) rescues a subset of fragile X related phenotypes in the FMR1 knockout mouse.
    Pacey LK; Doss L; Cifelli C; van der Kooy D; Heximer SP; Hampson DR
    Mol Cell Neurosci; 2011 Mar; 46(3):563-72. PubMed ID: 21215802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Agmatine relieves behavioral impairments in Fragile X mice model.
    Jeon SJ; Kwon H; Bae HJ; Gonzales EL; Kim J; Chung HJ; Kim DH; Ryu JH; Shin CY
    Neuropharmacology; 2022 Nov; 219():109234. PubMed ID: 36057317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dysregulated NMDA-Receptor Signaling Inhibits Long-Term Depression in a Mouse Model of Fragile X Syndrome.
    Toft AK; Lundbye CJ; Banke TG
    J Neurosci; 2016 Sep; 36(38):9817-27. PubMed ID: 27656021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.